Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

BACKGROUND: The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor. METHODS: In this international, phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with large B-cell lymphoma that was refractory to or...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	NEW ENGLAND JOURNAL OF MEDICINE 2022-02, Vol.386 (7), p.640-654
Hauptverfasser:	Locke, F.L, Miklos, D.B, Jacobson, C.A, Perales, M.-A, Kersten, M.-J, Oluwole, O.O, Ghobadi, A, Rapoport, A.P, McGuirk, J, Pagel, J.M, Munoz, J, Farooq, U, van Meerten, T, Reagan, P.M, Sureda, A, Flinn, I.W, Vandenberghe, P, Song, K.W, Dickinson, M, Minnema, M.C, Riedell, P.A, Leslie, L.A, Chaganti, S, Yang, Y, Filosto, S, Shah, J, Schupp, M, To, C, Cheng, P, Gordon, L, Westin, J.R
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!